Table 1. Flow analysis of leukocytes... | Rockefeller University Press

Table 1.

Flow analysis of leukocytes infiltrating solid Stage III/IV human ovarian tumors

Patients	Gated on CD45		Gated on CD11c⁺HLA-DR⁺		Gated on Dec205⁻	Gated on CD45
	CD11c⁺	CD11c⁺HLA-DR⁺	Dec205⁺	Dec205⁻	CD11b⁺CD14⁺	CD20⁺	CD3⁺
S1 Patient 1	52	30.9	39.9	61.7	28.6	1.78	30.9
S2 Patient 2	47.2	47.1	59.1	39.4	29.2	2.79	45.7
S4 Patient 3 (P)	84.7	82.2	17.2	81.2	4.9	n/a	n/a
S5 Patient 3 (M)	84.8	56.3	12	76.8	15.6	n/a	n/a
S6 Patient 4	12	12.3	70.3	30.1	44.5	n/a	n/a
S7 Patient 5	57.1	56.5	70.3	25.8	21.5	n/a	n/a
S8 Patient 6	52.8	52.4	41.3	59.9	7.04	1.78	30.9
S9 Patient 7	41.7	40	n/a	n/a	n/a	0.27	10.2
S10 Patient 8	28.2	6.35	n/a	n/a	n/a	0.013	0.49
S11 Patient 9	37.2	36.5	n/a	n/a	n/a	2.85	8.34
S12 Patient 10	37.1	5.4	n/a	n/a	n/a	0.045	1.92

Patients	Gated on CD45		Gated on CD11c⁺HLA-DR⁺		Gated on Dec205⁻	Gated on CD45
	CD11c⁺	CD11c⁺HLA-DR⁺	Dec205⁺	Dec205⁻	CD11b⁺CD14⁺	CD20⁺	CD3⁺
S1 Patient 1	52	30.9	39.9	61.7	28.6	1.78	30.9
S2 Patient 2	47.2	47.1	59.1	39.4	29.2	2.79	45.7
S4 Patient 3 (P)	84.7	82.2	17.2	81.2	4.9	n/a	n/a
S5 Patient 3 (M)	84.8	56.3	12	76.8	15.6	n/a	n/a
S6 Patient 4	12	12.3	70.3	30.1	44.5	n/a	n/a
S7 Patient 5	57.1	56.5	70.3	25.8	21.5	n/a	n/a
S8 Patient 6	52.8	52.4	41.3	59.9	7.04	1.78	30.9
S9 Patient 7	41.7	40	n/a	n/a	n/a	0.27	10.2
S10 Patient 8	28.2	6.35	n/a	n/a	n/a	0.013	0.49
S11 Patient 9	37.2	36.5	n/a	n/a	n/a	2.85	8.34
S12 Patient 10	37.1	5.4	n/a	n/a	n/a	0.045	1.92

Gating strategy is outlined in Fig. 2 H. n/a, insufficient material. Values are expressed as percentages.